Malta vs Syrian Arab Republic: Access to anti-retroviral drugs, female
Malta
47.0%
in 2024
Syrian Arab Republic
41.0%
in 2024
Malta rank
124th
Syrian Arab Republic rank
127th
Access to anti-retroviral drugs, female over time
- Malta
- Syrian Arab Republic
How they compare
Malta currently reports 47.0% against 41.0% in Syrian Arab Republic, a difference of 6.0%.
That makes Malta's figure about 1.1 times Syrian Arab Republic's.
Across all 25 years both countries report, Malta has been ahead every year.
Malta ranks 124th and Syrian Arab Republic ranks 127th of 141 countries.
Malta has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Malta | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 24.5% | 5.4% | 19.1% | Malta |
| 2010s | 49.1% | 26.9% | 22.2% | Malta |
| 2020s | 68.4% | 41.4% | 27.0% | Malta |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Malta or Syrian Arab Republic?
- Malta, at 47.0% against 41.0% in Syrian Arab Republic as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Malta and Syrian Arab Republic?
- 6.0%, with Malta ahead.
- How many years of comparable data are there for Malta and Syrian Arab Republic?
- 25 years are reported by both, from 2000 to 2024.
- How do Malta and Syrian Arab Republic rank globally for access to anti-retroviral drugs, female?
- Malta ranks 124th and Syrian Arab Republic ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.